Login
Manage Portfolio
Post a StockTalk
Write an Instablog
Get Daily Email Alert
Seeking Alpha
Home
The Macro View
Stocks & Sectors
Global Markets
ETFs
Investing Ideas
Breaking News
Transcripts
Business Intelligence
Amicus Therapeutics Inc. (FOLD)
(
)
Quotes
Dashboard
Chart
Historical Prices
Options
Analysis
Articles
Instablogs
StockTalks
Sentiment
Comments
News & PR
Market Currents
Buzz
Twitter: FOLD
Coverage
Top Authors
Cramer
Top Analysts
Business Intelligence
Transcripts
Events
Key Developments
Earnings
History & Projected
Consensus
Peer Earnings
Filings
SEC Filings
Annual Report
Ownership
Major Holders
Insider Trades
Insider Sentiment
Index Membership
Short Interest
Financials
Income Statement
Balance Sheet
Cash Flow
Company
Wikipedia Profile
Officers & Directors
Executive Comp
Analysis - Latest Articles
by
most recent
|
most commented
Developments for Parkinson's Disease Ignite Investor Enthusiasm
Nov 16
•
Michael Becker
•
5 Comments
Trial Setback Is Welcome News for Genzyme, But Don't Get Too Excited
Oct 6
•
Mark Mitchell
•
3 Comments
Sell Genzyme Near Term Due to Continued Manufacturing Challenges
Sep 24
•
Mark Mitchell
•
2 Comments
Treating Parkinson’s Disease - Investment Opportunities and Challenges
Aug 3
•
Michael Becker
•
1 Comment
Genzyme's Manufacturing Disruption Highlights Investment Opportunities
Jul 20
•
Michael Becker
•
4 Comments
Shares of HGSI Up Big in Anticipation of Clinical Trials Update
Jul 16
•
M. E. Garza
•
1 Comment
Amicus Therapeutics: Amigal Drug Shows Promise
Jul 7
•
Zacks.com
•
Comment!
FDA Calendar Updates: Amgen, Amicus, Oncothyreon and Medarex
Jun 23
•
Mike Havrilla
•
1 Comment
Pending Clinical Trial Results: Ten Extreme Trades
May 14
•
Mike Havrilla
•
8 Comments
FDA, Clinical Trial Calendars: Nine 'Cash Plus Catalyst' Trades
May 10
•
Mike Havrilla
•
Comment!
Chink in the Biotechnology Armor
Mar 1
•
Michael Becker
•
4 Comments
Three 'Busted' Biotech IPOs: Amicus, Jazz, Sirtris
Jul 11, 2007
•
Michael Shulman
•
2 Comments
This Week's IPOs: Amicus Therapeutics, Jazz Pharmaceuticals, LDK Solar, Response Genetics
May 28, 2007
•
SA Editor Abbi Adest
•
Comment!
Amicus IPO: A Very Risky Prospect (AMTX)
May 18, 2006
•
Evelyn Rubin
•
Comment!